Inventiva (NASDAQ:IVA) Sees Large Volume Increase – Should You Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw unusually-strong trading volume on Friday . Approximately 33,751 shares traded hands during trading, a decline of 5% from the previous session’s volume of 35,615 shares.The stock last traded at $5.96 and had previously closed at $5.87.

Analysts Set New Price Targets

Several equities research analysts have recently commented on IVA shares. Canaccord Genuity Group restated a “buy” rating and set a $20.00 price target on shares of Inventiva in a research note on Tuesday, September 30th. Guggenheim upped their price target on Inventiva from $9.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. HC Wainwright increased their price objective on Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research report on Saturday. Finally, Wall Street Zen upgraded Inventiva to a “hold” rating in a research report on Saturday, October 18th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $16.14.

Inventiva Price Performance

The company has a fifty day simple moving average of $5.43 and a two-hundred day simple moving average of $4.10.

Institutional Trading of Inventiva

An institutional investor recently bought a new position in Inventiva stock. Creative Planning bought a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $32,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.